Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Account Payables (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Change in Account Payables for 5 consecutive years, with $324527.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 45.03% year-over-year to $324527.0, compared with a TTM value of $1.5 million through Dec 2025, up 60.59%, and an annual FY2025 reading of $1.5 million, up 60.59% over the prior year.
  • Change in Account Payables was $324527.0 for Q4 2025 at SAB Biotherapeutics, down from $335924.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $684171.0 in Q1 2025 and bottomed at -$2.9 million in Q4 2021.
  • Average Change in Account Payables over 5 years is -$211081.6, with a median of -$16778.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 3216.08% in 2022, while the deepest fall reached 3568.97% in 2022.
  • Year by year, Change in Account Payables stood at -$2.9 million in 2021, then skyrocketed by 73.5% to -$777058.0 in 2022, then soared by 86.39% to -$105773.0 in 2023, then soared by 658.16% to $590385.0 in 2024, then plummeted by 45.03% to $324527.0 in 2025.
  • Business Quant data shows Change in Account Payables for SABS at $324527.0 in Q4 2025, $335924.0 in Q3 2025, and $138171.0 in Q2 2025.